BTOG 2019 | Vinorelbine in Mesothelioma: the upcoming VIM trial

Dean Fennell

Dean Fennell, PhD, FRCP, of the University Hospitals Of Leicester NHS Trust, Leicester, UK, tells us about an exciting trial to watch out for in mesothelioma. The Vinorelbine in Mesothelioma (VIM; NCT02139904) trial is potentially practice-changing, with results expected later this year. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference in Dublin, Ireland.

Share this video